March 7, 2017
Mereo to continue testing inhibitor for certain obese men with all three doses
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.